scholarly journals Author's reply to: “Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group”

2012 ◽  
Vol 132 (7) ◽  
pp. 1719-1720
Author(s):  
Sebastian Stintzing ◽  
Volker Heinemann
Keyword(s):  
Colorectal Cancer ◽  
Signal Transduction ◽  
Metastatic Colorectal Cancer ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Signal Transduction Pathway ◽  
Study Group ◽  
Transduction Pathway ◽  
Colorectal Cancer Patients

scholarly journals Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients

2020 ◽  
Vol 11 (5) ◽  
pp. 1063-1074
Author(s):  
Dong-Dong Yang ◽  
Zhan-Hong Chen ◽  
De-Shen Wang ◽  
Hong-En Yu ◽  
Jia-Huan Lu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Apolipoprotein B ◽  
Prognostic Value ◽  
Apolipoprotein A ◽  
Colorectal Cancer Patients

Prognostic value of biomarkers in metastatic colorectal cancer patients

2015 ◽  
Vol 194 (2) ◽  
pp. 343-350 ◽  
Author(s):  
Kozo Kataoka ◽  
Akiyoshi Kanazawa ◽  
Akio Nakajima ◽  
Ayane Yamaguchi ◽  
Akira Arimoto
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Colorectal Cancer Patients

scholarly journals Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses

2002 ◽  
Vol 20 (12) ◽  
pp. 2832-2843 ◽  
Author(s):  
Marie-Christine Etienne ◽  
Maurice Chazal ◽  
Pierre Laurent-Puig ◽  
Nicolas Magné ◽  
Christophe Rosty ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Promoter Polymorphism ◽  
Risk Of Death ◽  
Biopsy Specimens ◽  
Colorectal Cancer Patients

PURPOSE: The aim of this multicenter prospective study was to evaluate the role of intratumoral parameters related to fluorouracil (FU) sensitivity in 103 metastatic colorectal cancer patients receiving FU–folinic acid. PATIENTS AND METHODS: Liver metastatic biopsy specimens were obtained for all patients and primary tumor biopsy specimens for 54 patients. Thymidylate synthase (TS), folylpolyglutamate synthetase, and dihydropyrimidine dehydrogenase were measured by radioenzymatic assays; TS promoter polymorphism (2R/2R v 2R/3R v 3R/3R) was determined by polymerase chain reaction; and p53 protein and mutations were analyzed by immunoluminometric assay and denaturing gradient gel electrophoresis, respectively. RESULTS: p53 mutations were observed in 56.7% of metastases. TS activity was significantly higher in 2R/3R tumors as compared with 2R/2R or 3R/3R. TS activity in metastasis was the only parameter linked to clinical responsiveness (responders exhibited the lower TS, P = .047). Univariate Cox analyses demonstrated that TS activity in primary tumor (the greater the TS, the poorer the survival; P = .040), TS promoter polymorphism in primary tumor (risk of death of 2R/3R v 2R/2R, 2.68; P = .035), and p53 stop mutation in metastasis (risk of death of stop mutations v wild type, 3.14; P = .018) were the only significant biologic predictors of specific survival. Stepwise analysis did not discriminate between TS activity and TS polymorphism. CONCLUSION: Present results confirm the value of tumoral TS activity for predicting FU responsiveness, point out the importance of detailed p53 mutation analysis for predicting survival, and suggest that TS genotype in primary tumor carries a prognostic value similar to that of TS activity.

Sign in / Sign up

Export Citation Format

Share Document